LIVN
HealthcareLivaNova PLC · Medical - Devices · $4B
What is LivaNova PLC?
LivaNova PLC is a global medical device company focused on therapeutic solutions spanning cardiac surgery, neuromodulation, and circulatory support. Headquartered in London, the company serves hospitals, physicians, and healthcare providers across multiple continents.
LivaNova generates revenue across three segments. Its Cardiopulmonary segment supplies heart-lung machines, oxygenators, and related perfusion products used during cardiac surgery. The Neuromodulation segment markets the VNS Therapy System — an implantable device delivering vagus nerve stimulation for drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. The Advanced Circulatory Support segment provides temporary life support solutions for critically ill patients. Products are sold through direct sales teams and independent distributors worldwide.
LivaNova was formed in 2015 and is headquartered in London, United Kingdom.
- VNS Therapy System for epilepsy and depression
- Heart-lung machines and oxygenators for cardiac surgery
- Autotransfusion and perfusion tubing systems
- Temporary cardiopulmonary and respiratory life support products
- VITARIA System in development for heart failure via VNS
Is LIVN a Good Stock to Buy?
UQS Score rates LIVN as Below Average overall.
Among the five pillars, Valuation stands out as Attractive, suggesting the market may not be fully pricing in the company's longer-term potential. Quality, Moat, Growth, and Risk all register as Neutral — meaning LivaNova neither leads nor significantly lags the broader healthcare device sector on these dimensions.
The absence of standout scores across Quality, Moat, and Growth pillars indicates LivaNova has not yet demonstrated the durable competitive advantages or consistent expansion that typically characterize higher-rated medical device peers.
See the full pillar breakdown and detailed financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does LIVN pay dividends?
No — LivaNova PLC does not currently pay a dividend.
LivaNova does not currently pay a dividend. For a medical device company operating across multiple development-stage programs — including clinical trials for new VNS indications — retaining capital to fund research, regulatory pathways, and commercial expansion is a common strategic choice. Income-focused investors should factor this into their assessment.
When does LIVN report earnings?
LivaNova reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Across recent reporting periods, LivaNova's results have reflected the dynamics of a multi-segment medical device business — balancing mature cardiopulmonary revenues with growth investments in neuromodulation and circulatory support. Segment-level performance and guidance updates are the key items investors typically track each quarter.
For the most recent quarter's results and upcoming reporting dates, visit LivaNova's official investor relations page.
LIVN Price History
-22.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in LivaNova PLC?
Based on LivaNova PLC's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
LIVN Long-term Outlook
With Growth and Risk pillars both rated Neutral, LivaNova's fundamental trajectory appears measured rather than accelerating. The Attractive Valuation pillar suggests there may be room for re-rating if the company can convert its pipeline — particularly expanded VNS indications and the VITARIA System — into consistent top-line momentum. Execution risk remains a factor given the regulatory and clinical complexity of its development programs.
Growth drivers
- Expansion of VNS Therapy into new indications such as obstructive sleep apnea
- Potential commercialization of the VITARIA System for heart failure
- Growing global demand for advanced circulatory support in critical care settings
Key risks
- Regulatory and clinical trial uncertainty across multiple pipeline programs
- Competitive pressure in both the cardiac surgery and neuromodulation device markets
- Execution risk in scaling newer segments while maintaining cardiopulmonary revenues
LIVN vs Peers
LivaNova operates in a competitive medical device landscape alongside companies focused on organ transplant logistics, cardiac monitoring, and device component manufacturing.
TransMedics focuses on organ care systems for transplantation, occupying a distinct niche from LivaNova's neuromodulation and cardiac surgery portfolio.
iRhythm specializes in wearable cardiac monitoring technology, competing in the broader cardiac diagnostics space rather than surgical or implantable therapy devices.
Integer Holdings is a contract manufacturer of medical device components, serving as a supplier to the broader industry rather than a direct therapy provider like LivaNova.
Frequently Asked Questions
What does LivaNova do?
LivaNova is a medical device company that develops and sells products across three areas: cardiopulmonary support for cardiac surgery, neuromodulation therapies using vagus nerve stimulation, and temporary advanced circulatory support for critically ill patients. Its products are used by surgeons, neurologists, and critical care physicians in hospitals worldwide.
Does LIVN pay dividends?
LivaNova does not currently pay a dividend. The company retains capital to fund its ongoing research programs, clinical trials for new VNS indications, and commercial development across its three business segments. Investors seeking income should note this before investing.
When does LIVN report earnings?
LivaNova follows a standard quarterly earnings cadence for US-listed companies. Specific dates are not covered by our data source — check LivaNova's investor relations page for the most current reporting schedule and recent results.
Is LIVN a good stock to buy?
UQS Score rates LIVN as Below Average overall. The Valuation pillar is Attractive, which may interest value-oriented investors, but Quality, Moat, Growth, and Risk all sit at Neutral. Whether that profile fits your investment criteria depends on your own goals and risk tolerance. The full pillar breakdown is available to Pro members.
Is LIVN overvalued?
Based on the UQS Valuation pillar, LIVN is rated Attractive — meaning the current market price appears reasonable or potentially favorable relative to the company's fundamentals. This does not constitute a price target or guarantee of future returns. View the complete valuation analysis with a Pro account.
How does LIVN compare to its competitors?
LivaNova competes in adjacent areas of the medical device market alongside TransMedics Group, iRhythm Technologies, and Integer Holdings. Each company occupies a distinct niche — from organ transplant systems to cardiac monitoring to component manufacturing. LivaNova's multi-segment model spanning surgery, neuromodulation, and circulatory support differentiates its revenue mix.
What is LIVN's market cap bracket?
LivaNova is classified as a mid-cap company. This places it in a segment of the market that typically carries more liquidity than small-caps but less institutional coverage than large-cap peers — a common profile for specialized medical device companies with focused therapeutic portfolios.
Who founded LivaNova?
LivaNova PLC was formed in 2015 through the merger of Sorin Group and Cyberonics. The combined entity brought together Sorin's cardiac surgery expertise and Cyberonics' established VNS Therapy platform, creating a diversified medical device company headquartered in London.
Is LIVN a long-term quality indicator?
As a long-term quality indicator, LIVN's UQS Score of Below Average reflects Neutral readings across Quality, Moat, and Growth pillars. Investors with a long-term horizon may weigh the Attractive Valuation against the absence of standout competitive advantages. The full five-pillar analysis is available to Pro members on UQS Score.
What is the main competitive advantage of LivaNova?
LivaNova's primary differentiation lies in its VNS Therapy System, which holds regulatory approvals for drug-resistant epilepsy and difficult-to-treat depression — conditions with limited treatment alternatives. Its established relationships with neurologists and neurosurgeons, combined with an active pipeline for new indications, form the core of its competitive positioning.
What sector does LIVN belong to?
LivaNova operates in the Healthcare sector, specifically within the medical devices industry. Its products span cardiac surgery support, implantable neuromodulation devices, and critical care circulatory support — placing it at the intersection of several high-need therapeutic areas. Explore other [healthcare device stocks](/sector/healthcare) on UQS Score.
Unlock Full LIVN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access detailed financial metrics and trend data
- ✓Compare LIVN against sector peers side by side
- ✓See the complete valuation and risk breakdown
- ✓Track score changes with portfolio watchlist alerts
Pro Analysis
LIVN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | 52.7 | 50.3 | 40.0 | 47.2 | 70.4 | 67.4 | +4.0 |
| May 7, 2026 | 48.7 | 40.1 | 40.0 | 45.9 | 49.0 | 81.3 | -0.5 |
| May 3, 2026 | 49.2 | 40.1 | 40.0 | 45.9 | 49.0 | 84.6 | +0.3 |
| Apr 26, 2026 | 48.9 | 40.1 | 40.0 | 45.9 | 49.0 | 82.6 | +0.2 |
| Apr 19, 2026 | 48.7 | 40.1 | 40.0 | 45.9 | 49.0 | 80.8 | -0.4 |
| Apr 14, 2026 | 49.1 | 40.8 | 40.0 | 45.9 | 49.0 | 82.5 | -0.1 |
| Apr 12, 2026 | 49.2 | 40.8 | 40.0 | 45.9 | 49.0 | 83.5 | +0.1 |
| Apr 10, 2026 | 49.1 | 40.7 | 40.0 | 45.9 | 49.0 | 82.8 | +0.1 |
| Apr 9, 2026 | 49.0 | 40.5 | 40.0 | 45.8 | 49.0 | 82.8 | -0.1 |
| Apr 5, 2026 | 49.1 | 40.6 | 40.0 | 45.8 | 49.0 | 82.8 | +0.1 |
LIVN — Pillar Breakdown
Quality
— 50.2/100 (25%)LivaNova PLC has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 47.2/100 (20%)LivaNova PLC shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 70.4/100 (15%)LivaNova PLC maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 67.0/100 (15%)LivaNova PLC trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 40/100 (25%)LivaNova PLC possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for LIVN.
Score Composition
Financial Data
More Stock Analysis
How is the LIVN UQS Score Calculated?
The UQS (Unified Quality Score) for LivaNova PLC is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses LivaNova PLC's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether LivaNova PLC is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.